GovChime
Notice ID: 16122805e23b47e5bf10e37ede1823f6Special Notice

AN41--ATTN TARA DOSSIEMA Define behavioral deficits associated with TBI and PTSD

Archived on August 3, 2024. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
9:00 AM UTC−04:00
Posted
June 28, 2024
Notice type
Special Notice

Notice details

Office
241-NETWORK CONTRACT OFFICE 01 (36C241)
Last updated
Dec 6, 2025

Identifiers

Solicitation number
36C24124Q0678
Notice ID
16122805e23b47e5bf10e37ede1823f6

Description

Pre-Solicitation Notice for a sole source. This is not a solicitation. The Department of Veterans Affairs intends to negotiate a requirement with the Mary Hitchcock Memorial Hospital on behalf of Dartmouth-Hitchcock Clinic (MHMH/DHC). The applicable NAICS code is 541715. The PSC is AN41. The authority for this action is FAR 13.106-1(b)(2): Only one Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. Interested persons may contact the Contracting Specialist via email at ophelia.wilson@va.gov regarding this procurement. The determination to conduct a competitive procurement based on responses to this notice is solely within the discretion of the Contracting Officer. PERFORMANCE WORK STATEMENT Biomarker Development to Guide Personalized Interventions for Traumatic Brain Injury and Posttraumatic Stress Disorder (PTSD) INTRODUCTION: The mission of VA s National Center for PTSD (NCPTSD) is to advance the clinical care and social welfare of America's Veterans and others who have experienced trauma, or who suffer from PTSD, through research, education, and training in the science, diagnosis, and treatment of PTSD and stress-related disorders. We generate, collate, synthesize, disseminate, and promote implementation of the best information about PTSD. SCOPE: Traumatic brain injury (TBI) and PTSD are significant problems for military personnel and Veterans. These conditions can impose extensive quality of life burdens on affected individuals. Brain injury and PTSD are characterized by disrupted communication between brain regions that can result in neuropsychiatric symptoms, including depression, anxiety, hyperarousal, social avoidance, impaired fear, and maladaptive decision making. There is a growing interest in utilizing targeted brain stimulation to improve TBI and PTSD, however, prior to widespread application, there is a critical need to define biomarkers associated with specific domains of impairment. It has been proposed that this knowledge will help guide personalized interventions that are tailored according to symptomatology. The overarching goal of the current project is to define the utility of clinically-relevant biomarkers to guide treatment. The project will focus on systems-level brain activity as a neural biomarker and blood proteins as a peripheral biomarker of hypothalamic-pituitary-adrenal (HPA) axis activity. The project will utilize a subject model of TBI with and without PTSD. Following experimental injuries, subjects will undergo treatment which will include targeted brain stimulation and psychedelic agents. The proposed work supports ongoing collaborative research currently conducted by investigators at the White River Junction VA. Key activities to be performed include: 1) Define behavioral deficits, 2) Define treatment effects, and 2) Develop biomarkers to guide personalized treatment. PERIOD AND PLACE OF PERFORMANCE: The place of performance will be at both the White River Junction VA Healthcare System (WRJ-VAHS) and the contractor location, Mary Hitchcock Memorial Hospital for itself and on behalf of Dartmouth-Hitchcock Clinic (MHMH/DHC). Approximately 25% of the work will be performed in the Neuro-Immune Laboratory at WRJ-VAHS, and the other 75% of work will be performed in a laboratory at MHMH/DHC. The contract location should be located within a 30-minute drive of the WRJ facility to ease transportation of the subjects. It has been determined that transportation can be feasibility performed, due to shared veterinary resource agreement between locations. BACKGROUND: The WRJ Translational Neuroscience Research Group aims to identify and evaluate novel, interventions for TBI and PTSD. As part of this work, the group aims to define clinically-relevant biomarkers to guide treatment implementation. The current study will employ subject models of TBI and/or PTSD where animals will receive experimental injuries and will receive brain stimulation with and without psychedelic agents. The current project will employ validated pre-clinical behavioral assays to assess multiple domains of impairment, including hyperarousal, social interactions, appetitive behaviors, and executive function. Animals will be assessed at various time points post-injury. Neural and blood-based biomarkers will be collected to assess how systems-level brain activity and hypothalamic-pituitary-adrenal (HPA) axis activity, respectively, relate to behavioral deficits and response to treatment. PERFORMANCE OBJECTIVES/DELIVERY SCHEDULE: Define behavioral deficits associated with TBI and PTSD (deliver data set and report within 6 months of contract start date). Determine the utility of neural activity and/or blood-based biomarkers to identify animals with behavioral deficits (deliver data set and report within 6 months of contract start date). Determine the utility of treatment to improve behavioral deficits (deliver data set and report defining proof-of-concept data within 12 months of contract start date). Determine the utility of neural and/or blood-based biomarkers to personalize treatment (deliver data set and report within 12 months of contract start date). Acceptable completion of deliverables will be determined through receipt of complete data sets that include details of all procedures, behavioral outcomes, and statistical comparisons. All deliverables include estimated personnel and supply costs associated with planned studies. PUBLICATION/COLLABORATION ON RESULTS: The VA and MHMH/DHC will maintain joint ownership of work product and intellectual property rights. OTHER REQUIREMENTS: Prior to commencement of work described, all personnel will be required to obtain and maintain all appropriate certifications for performing preclinical research at the VA and MHMH/DHC, including CITI and Bioraft training, IACUC approval, and VA-Without Compensation (WOC) research affiliate designation. B.3 PRICE/COST SCHEDULE ITEM INFORMATION ITEM DESCRIPTION OF QUANTITY UNIT NUMBER SUPPLIES/SERVICES 0001 1.00 JB Define behavioral deficits associated with TBI and PTSD Estimated Invoice: 6 months 0002 1.00 JB Determine the utility of neural biomarkers to identify animals with behavioral deficits. Estimated Invoice: 6 months 0003 1.00 JB Determine the utility of treatment to improve behavioral deficits. Estimated Invoice: 12 months 0004 1.00 JB Determine the utility of neural biomarkers to personalize treatment. Estimated Invoice: 12 months Records Management: The following standard items relate to records generated in executing the contract and should be included in a typical procurement contract: Citations to pertinent laws, codes and regulations such as 44 U.S.C chapters 21, 29, 31 and 33; Freedom of Information Act (5 U.S.C. 552); Privacy Act (5 U.S.C. 552a); 36 CFR Part 1222 and Part 1228. Contractor shall treat all deliverables under the contract as the property of the U.S. Government for which the Government Agency shall have unlimited rights to use, dispose of, or disclose such data contained therein as it determines to be in the public interest. Contractor shall not create or maintain any records that are not specifically tied to or authorized by the contract using Government IT equipment and/or Government records. Contractor shall not retain, use, sell, or disseminate copies of any deliverable that contains information covered by the Privacy Act of 1974 or that which is generally protected by the Freedom of Information Act. Contractor shall not create or maintain any records containing any Government Agency records that are not specifically tied to or authorized by the contract. The Government Agency owns the rights to all data/records produced as part of this contract. The Government Agency owns the rights to all electronic information (electronic data, electronic information systems, electronic databases, etc.) and all supporting documentation created as part of this contract. Contractor must deliver sufficient technical documentation with all data deliverables to permit the agency to use the data. Contractor agrees to comply with Federal and Agency records management policies, including those policies associated with the safeguarding of records covered by the Privacy Act of 1974. These policies include the preservation of all records created or received regardless of format [paper, electronic, etc.] or mode of transmission [e-mail, fax, etc.] or state of completion [draft, final, etc.]. No disposition of documents will be allowed without the prior written consent of the Contracting Officer. The Agency and its contractors are responsible for preventing the alienation or unauthorized destruction of records, including all forms of mutilation. Willful and unlawful destruction, damage or alienation of Federal records is subject to the fines and penalties imposed by 18 U.S.C. 2701. Records may not be removed from the legal custody of the Agency or destroyed without regard to the provisions of the agency records schedules. Contractor is required to obtain the Contracting Officer's approval prior to engaging in any contractual relationship (sub-contractor) in support of this contract requiring the disclosure of information, documentary material and/or records generated under, or relating to, this contract. The Contractor (and any sub-contractor) is required to abide by Government and Agency guidance for protecting sensitive and proprietary information.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:36C24124Q0678
  1. Special NoticeCurrentJun 28, 2024

    AN41--ATTN TARA DOSSIEMA Define behavioral deficits associated with TBI and PTSD

    Notice 16122805e23b47e5bf10e37ede1823f6 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
INTENT TO SOLE SOURCE GENERAL INFORMATION Network Contracting Office (NCO) 22 Attn: Charity Cazee Department of Veteran Affairs 3601 S. 6TH Avenue, Bldg. 45 Tucson, Arizona 85723 (520) 792-1450 Ext. 16236 Intent to Sole Source: The Government intends to make a sole award firm-fixed-price contract in accordance with Federal Acquisition Regulations (FAR) 6.302-2 Only One Source in conjunction with FAR 13.5 Simplified Procedures for Certain Commercial Items. The requirement is to provide NOVOCYTE 3000 PM&R SERVICES. SERVICE to PROVIDE comprehensive service and maintenance agreement for the laboratory's Agilent NovoCyte 3000 benchtop flow cytometer, including the associated NovoSampler Pro automated sample loader, instrument workstation and Agilent NovoExpress acquisition/analysis software; VETERAN AFFAIRS SAN DIEGO HEALTH CARE SERVICES (VASDHCS) campuses. The intended source is AGILENT TECHNOLOGIES, INC. In accordance with FAR 22.1003-3(e) and FAR Part 6, contracts awarded using this authority shall be supported by a written justification and approval described in FAR 6.303 and 6.304; as applicable, the justification will be posted within fourteen (14) days after contract award. The Government will consider all capability statements received by this synopsis's closing date. The Government's determination not to compete based on responses to this notice is solely within the Government's discretion. Information received will be considered strictly to determine whether to conduct a competitive procurement. The applicable North American Industrial Classification System Code (NAICS) code that this work falls under is 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). THIS NOTICE OF INTENT IS NOT A REQUEST FOR COMPETITIVE QUOTATIONS. All capable sources must provide past performance experience in similar research services and be a licensed provider (whichever applies to the requirement). All the above information should be included in the vendors' capability in response to this notice. All inquiries and submittals must be sent via email to Charity.Cazee@va.gov no later than 12:00 PM Pacific Time (PT), 11/13/2026. Please ensure notice # 36C26227Q0114 is cited on all submitted documents. This is a follow-on, base plus four option years, Firm-Fixed-Price contract.
54%
Special Notice11/13/2026
54%
AwardedOpen
54%
AwardedOpen
The Advanced Research Projects Agency for Health (ARPA-H) Emerging Health Innovators (EHI) aims to or seeks to ensure ARPA-H identifies and engages early career investigators. To achieve this goal, ARPA-H is soliciting proposals from these researchers and innovators and their organizations to develop cutting-edge biomedical, health, and community-engaged research and innovation. ARPA-H anticipates multiple Other Transaction awards resulting from this announcement Amendment 1: This amendment clarifies the number of submissions that may be submitted by each offeror. See section 2.4 of the ISO. It also updates the solution summary cover sheet and the FAQ. Amendment 2: This amendment uploads two question and answer documents.
53%
Solicitation02/10/2027
The Defense Health Agency Contracting Activity (DHACA) on behalf of the WRAIR, CMPN, ISB, intends to negotiate on a sole source basis in accordance with RFO 6.103 with vendor Mitochon Pharmaceuticals, Inc. 970 Cross Lane, Blue Bell, PA 19422-1574. The contractor shall supply two (2) Batches of the proprietary prodrug MP201 to ISB for testing Acute Stress Reactions (ASRs). This includes providing quality control documentation and dosage background information. Additionally, the contractor shall provide informational support to the ISB research team by assisting with preparing reports and manuscripts related to MP201. Each batch of synthesized MP201 shall consist of a freshly made lot of prodrug to determine target dosage in the range of approximately 8 - 80 mg/kg body weight. These doses shall be developed in quantities to support oral administration in mice. THIS NOI IS NOT A REQUEST FOR COMPETITIVE PROPOSALS, and no solicitation document exists for this requirement. Meaningful submissions received in response to this notice will be considered solely for the purpose of determining whether a competitive procurement is in the best interest of the Government.. Responsible, interested parties may identify their interest by submitting capability statements (using PDF, MS Word, or Excel attachments), in writing, by 2:00 p.m. Eastern Time, 31 December 2026 to Herbert Keen at herbert.e.keen.civ@health.mil and Mr. Lance Nowell at lance.l.nowell.civ@health.mil. Supporting evidence must be furnished in sufficient detail to demonstrate the firms ability to provide the stated capability. Information and materials submitted in response to this request WILL NOT be returned. DO NOT SUBMIT CLASSIFIED MATERIAL. Responses will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon responses to this notice is solely within the discretion of the Government. If no responses are received, the DHACA will proceed with the sole source contract issued to Mitochon Pharmaceuticals, Inc.
45%
Special Notice12/31/2026

Additional Details

Solicitation Number

36C24124Q0678

Archive Date

Aug 3, 2024

Office Address

TOGUS, ME, 04330